EGEGazette
Live
UAE Official Calls FlyDubai Plane Incident a "Serious Terrorist Act" Amid US Threats Against IranUS reportedly to deploy anti-ship missiles near Taiwan for the first timeTrump Threatens Iran with Severe Strike Over flydubai Plane IncidentUS Job Growth Slows Sharply in September as Unemployment Rate Rises to 4.2%Court Blocks Donald Trump From Firing Court-Appointed ProsecutorsTrump Threatens Iran With "Very Powerful Strike" If Confirmed Involved in FlyDubai Plane IncidentThird US aircraft carrier heads to Middle East as Trump signals intensified strikes on IranUS deploys 2,000 Marines to Middle East amid Iran war, tanker hit in HormuzGlobal Bond Sell-Off Deepens as UK Long-Term Borrowing Costs Top 6%Oil Tops $100 as US Bonds Post Their Worst Quarter Since 1994Brent Crude Tops $100 a Barrel Again Amid Uncertainty Over US-Iran Talks10-Year Treasury Yield Hits Highest Level Since 2002 Amid Global Bond Sell-Off
BusinessAI AnalysisReported

Big Pharma's China Deal Spree Grows With Latest Tie-Up Worth Up to $7.8 Billion

Western biopharmaceutical companies are increasingly turning to China to source innovation as the industry's looming patent cliff draws closer, according to CNBC.

By EGazette AI · · 1 min read · language: en

Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.

Article image
— CNBC — Top News

Western biopharmaceutical companies are increasingly striking deals with Chinese drugmakers, with the latest tie-up reported to be worth up to $7.8 billion, according to CNBC.

The deal is part of a broader trend in which Western pharma firms are turning to China to source innovative drug candidates, as the industry faces what has been described as a looming "patent cliff."

The patent cliff refers to a period in which a wave of blockbuster drugs are set to lose patent protection, exposing their manufacturers to generic competition and prompting a search for new revenue-generating treatments.

China's biotech sector has increasingly positioned itself as a source of early-stage drug innovation, attracting licensing and partnership interest from major Western pharmaceutical companies.

Further details on the specific companies involved in the latest deal, and the therapeutic area it covers, were not specified in the available report.

Sources

EGazette summarizes reporting from multiple sources; follow the links for the originals.

Comments

Sign in to join the conversation.

Forgot password?

No account?

Loading comments…

Related articles